{"id":"NCT04964089","sponsor":"Kodiak Sciences Inc","briefTitle":"A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)","officialTitle":"A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-06-23","primaryCompletion":"2023-03-28","completion":"2023-04-06","firstPosted":"2021-07-15","resultsPosted":"2024-05-02","lastUpdate":"2024-07-03"},"enrollment":557,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Wet Age-related Macular Degeneration"],"interventions":[{"type":"DRUG","name":"KSI-301","otherNames":[]},{"type":"DRUG","name":"Aflibercept","otherNames":["Eylea"]},{"type":"OTHER","name":"Sham Procedure","otherNames":[]}],"arms":[{"label":"KSI-301 (Treatment Group A)","type":"EXPERIMENTAL"},{"label":"Aflibercept (Treatment Group B)","type":"ACTIVE_COMPARATOR"}],"summary":"This Phase 3 study will evaluate the efficacy and safety of KSI-301 compared to aflibercept, in participants with neovascular (wet) age-related macular degeneration (wAMD)","primaryOutcome":{"measure":"Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48.","timeFrame":"Day 1 to Week 48","effectByArm":[{"arm":"KSI-301 (Treatment Group A)","deltaMin":2.5,"sd":0.78},{"arm":"Aflibercept (Treatment Group B)","deltaMin":4.6,"sd":0.76}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0083"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":66,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":276},"commonTop":["COVID-19","Neovascular age-related macular degeneration - Fellow eye","Conjunctival haemorrhage - Study eye","Urinary tract infection","Hypertension"]}}